ArticleAnnals of surgical oncology2026
Trends in Clinicopathologic and Treatment Outcomes in Patients with Gastric Adenocarcinoma in the United States Between 2004 and 2021.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ASO Author Reflections: Trends in Clinicopathologic, Treatment, and Outcomes of Patients with Gastric Adenocarcinoma in the United States Between 2004 and 2021.Annals of surgical oncology · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric adenocarcinoma (GAC) continues to be a significant global health challenge with shifting demographics, treatment approaches, and outcomes. Although innovations have improved care, there is still a lack of comprehensive, real-world, population-level data examining these changes over time in the USA.
methodsWe carried out a retrospective cohort study using the National Cancer Database from 2004 to 2021 to examine trends in patient demographics, treatment approaches, and clinical outcomes among 177,069 patients with GAC. The study was divided into three periods: 2004-2009, 2010-2015, and 2016-2021.
resultsThe use of laparoscopic and robotic approaches, neoadjuvant systemic therapy, and multi-agent chemotherapy has significantly increased, whereas rates of open surgery, adjuvant treatment, and single-agent regimens have declined. The use of immunotherapy rose significantly, from 0.1 to 10%. Surgical quality has improved, indicated by a higher number of lymph nodes retrieved. There were significant decreases in readmission rates, reductions in 30-day and 90-day mortality, and shorter lengths of stay. Although more patients are presenting with metastatic disease, the 3-year overall survival rate has increased significantly from 13.3 to 23.1%. Additionally, overall survival improved significantly across the periods, with median survival increasing from 12.4 months in P1 to 15.6 months in P2 and 17.9 months in P3 (p < 0.001).
conclusionThis national analysis highlights significant advancements in GAC management between 2004 and 2021, such as the adoption of minimally invasive surgery and advanced systemic therapies. These changes have led to better surgical quality and higher survival rates.
Indexed as
Identifiers
41233709What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.